FDA 483 - Annora Pharma Private Limited - January 20, 2023

Annora Pharma Private Limited, a manufacturer based in Hyderabad, Telangana, India, received an FDA Form 483 following an inspection conducted from January 16-20, 2023. The inspection revealed significant deficiencies in the company's adherence to current good manufacturing practice (cGMP) regulations, particularly concerning employee training.

The main issue cited was a pervasive failure to provide adequate training to employees on the specific operations they perform and the written procedures required by cGMP. Key observations included the Director Operations lacking training on Quality Unit responsibilities, and various Quality Assurance and Quality Control personnel not receiving training on critical Standard Operating Procedures (SOPs) such as change control, data integrity, quality risk management, document control, and product recall programs. Even production staff were found untrained on essential equipment operation and cleaning procedures. Furthermore, training records for some senior personnel were incomplete, failing to specify the training mode.

These findings indicate a substantial breakdown in Annora Pharma's quality system regarding personnel competency and compliance with established procedures. The firm is expected to address these inspectional observations by developing and implementing comprehensive corrective and preventive actions to ensure full compliance with regulatory standards for pharmaceutical manufacturing.